Xintela signs with Australian CRO for clinical study

Xintela's First-in-Human study with the stem cell product XSTEM, a combined phase I/II clinical study on patients with knee osteoarthritis, will be conducted in Australia and is planned to be initiated in Q4 2021. An agreement with the Contract Research Organisation (CRO) GreenLight Clinical (GLC), headquartered in Sydney, Australia, has now been signed. Xintela has collaborated with GLC since 2019, and this now continues with the full-service execution of the clinical study.

"We are very pleased to have selected GreenLight Clinical (GLC) as our partner in this First-In-Human study. We have for some time worked with GLC on regulatory matters and preparation of core clinical documents. We have established a productive working relationship and good foundation to continue our partnership as Xintela now enters clinical development of XSTEM. At the same time, Xintela is strengthening our clinical development team in-house, which is essential to successfully drive our clinical programs forward", says Xintela's CEO, Evy Lundgren-Åkerlund.

"We are delighted to partner with Xintela for the XSTEM-OA study, and further strengthen the close ties between our respective organizations. GreenLight and Xintela share a common goal of bringing new and innovative treatments to patients in need. With Australia's renowned clinical research environment, GreenLight's personal and customised approach will enable Xintela to rapidly advance the XSTEM program. We look forward to working closely once again with Xintela, and take this product into the clinic, and beyond", says GreenLight Clinical's CEO, Franz D'Lima.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About GreenLight Clinical
GreenLight Clinical is a full-service CRO specialised in early phase studies, based in Australia with operations across North America, Europe and Asia Pacific. For more information, please refer to www.greenlightclinical.com.

About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].

The following documents can be retrieved from beQuoted
Xintela-sign-contract-with-GLC-final-final.pdf

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.